Bruker Corporation Acquires NanoString Technologies Business
May 6, 2024
Bruker Corporation has acquired substantially all assets of NanoString Technologies, Inc. through a court-supervised Chapter 11 asset sale for approximately $392.6 million in cash plus assumption of certain liabilities. The deal, announced April 2024 and closed in late April/early May 2024, brings NanoString's spatial biology and gene-expression product lines into Bruker to preserve customer access, product development, and jobs while expanding Bruker's life‑science instrumentation capabilities.
- Buyers
- Bruker Corporation
- Targets
- NanoString Technologies, Inc.
- Sellers
- NanoString Technologies, Inc.
- Industry
- Medical Devices
- Location
- Washington, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Bruker Acquires Dynamic Biosensors GmbH
October 2, 2024
Biotechnology
Bruker Corporation has acquired Dynamic Biosensors GmbH, a Munich-based developer of single-cell interaction cytometry and biosensor instruments, to strengthen Bruker’s biosensors portfolio. The deal combines Dynamic Biosensors’ heliXcyto and heliX+ technologies with Bruker’s high-throughput SPR systems to expand capabilities and product offerings for drug discovery and biopharma research; financial terms were not disclosed.
-
Bruker Corporation Acquires Nion
January 3, 2024
Manufacturing
Bruker Corporation has acquired Nion, a Kirkland, Washington developer and manufacturer of high-end scanning transmission electron microscopes (STEM), including the UltraSTEM line and advanced EELS technology. The acquisition strengthens Bruker's materials science instrumentation portfolio and provides capabilities for electron diffraction crystallography; Nion reported approximately $8 million in revenue in 2023. Financial terms were not disclosed.
-
Bruker Corporation to Acquire PhenomeX Inc for $108 Million
August 17, 2023
Medical Devices
Bruker Corporation has signed a definitive agreement to acquire PhenomeX Inc in an all-cash transaction valued at approximately $108 million equity value ($1.00 per share). The deal is expected to close in the fourth quarter of 2023, subject to customary closing conditions, after which PhenomeX will merge into a wholly owned Bruker subsidiary.
-
Bruker Corporation to Acquire Neurescence Inc.
November 12, 2022
Healthcare Services
Bruker Corporation has signed a definitive agreement to purchase 100% of the shares of Neurescence Inc., an ultralight fiber-bundle Multiscopes provider for simultaneous multi-region optical functional neuroimaging. The acquisition is expected to create synergies with Bruker’s multiphoton and head-mounted miniscope offerings, expanding its reach in freely behaving animal imaging and photostimulation.
-
Bionano Genomics Acquires BioDiscovery
October 12, 2021
Software
Bionano Genomics agreed to acquire BioDiscovery, a provider of NxClinical genomics analysis software, in a deal worth up to $100 million in cash and equity. The acquisition will integrate BioDiscovery's platform-agnostic analysis and reporting tools with Bionano's optical genome mapping technology to accelerate variant analysis and broaden Bionano's market reach; BioDiscovery founder Soheil Shams will join Bionano as Chief Informatics Officer.
-
Bruker Corporation Acquires Canopy Biosciences, LLC
September 11, 2020
Biotechnology
Bruker Corporation has acquired Canopy Biosciences, LLC to strengthen its targeted multi-omics and high-plex biomarker imaging capabilities, adding Canopy's ChipCytometry platform and multi-omics services. Financial terms were not disclosed; Ampersand Capital Partners was identified as Canopy's lead investor.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.